Loay Kamel

Loay Kamel

Auto-generated profile, based on publicly available information

Loay Kamel

School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in AACE Endocrinology and Diabetes
Verified
Journal Article
Open access
LKLoay Kamel
Loay Kamel
AHAbdullah Hussain
Abdullah Hussain
AEAhmed Elmewafy
Ahmed Elmewafy
DADalal Ali
Dalal Ali
AKAliya A. Khan
Aliya A. Khan
X-linked hypophosphatemia (XLH) is a disorder caused by a pathogenic variant in the phosphate-regulating endopeptidase homolog X-linked gene. This leads to increased fibroblast growth factor 23 synthesis, prompting renal phosphate wasting and hypophosphatemia. Adults with XLH present with osteomalacia, chronic musculoskeletal pain, enthesopathy, osteoarthritis, fractures, and pseudofractures. We present a patient initially diagnosed with hypophosphatemic, nonrachitic bone disease. However, later genetic testing identified a pathogenic phosphate-regulating endopeptidase homolog X-linked variant (c.1645+1G>A), establishing an XLH diagnosis. A 50-year-old male was diagnosed with XLH through molecular testing at age 49. He was initially diagnosed at age 3 years with hypophosphatemic bone disease due to an unclear inheritance pattern. Treatment with phosphate and active vitamin D was started but discontinued at age 13 due to adverse effects, then resumed between ages 30 and 45. The patient presented with joint pain, abnormal gait, dental abscesses, and right hip replacement due to early-onset osteoarthritis with history of an atraumatic vertebral fracture at age 42. Labs showed hypophosphatemia, low tubular phosphate reabsorption, and elevated alkaline phosphatase and fibroblast growth factor 23. He was switched to burosumab therapy, resulting in clinical improvement. This case underscores the diagnostic challenges of atypical XLH, particularly when X-linked inheritance patterns are absent. It illustrates the transformative role of molecular diagnostics in establishing diagnoses. It also reports on the impact of burosumab therapy when initiated in adults. This case demonstrates hallmark biochemical and radiological features of XLH, and the value of genetic testing in establishing a definitive diagnosis, particularly in individuals with atypical or nonclassical presentations.

1 January 2026 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
AEAhmed Elmewafy
Ahmed Elmewafy
EJEyad Jamileh
Eyad Jamileh
AHAbdullah Hussain
Abdullah Hussain
LKLoay Kamel
Loay Kamel
OFOmar Farooq
Omar Farooq
IAIbrahim Antoun
Ibrahim Antoun
Introduction: Heart‐type fatty acid‐binding protein (H‐FABP) is rapidly released following myocardial injury, but its prognostic significance in acute coronary syndrome (ACS) remains uncertain. We evaluated the association between elevated H‐FABP and adverse clinical outcomes in confirmed or suspected ACS. Methods: PubMed, Embase, CENTRAL, Web of Science and Scopus were searched from inception to 30 August 2026 without date restriction. Studies assessing diagnostic and/or prognostic relevance of circulating H‐FABP in adults with confirmed or suspected ACS were eligible. Prognostic outcomes included all‐cause mortality, major adverse cardiovascular events (MACE), heart failure (HF)–related hospitalisation and recurrent myocardial infarction (MI). Risk of bias was assessed using QUIPS. Crude odds ratios (ORs) from extractable 2 × 2 event data were pooled using inverse‐variance random‐effects models with restricted maximum‐likelihood estimation. Results: Twelve studies were included, with five contributing to meta‐analysis. Elevated H‐FABP was associated with higher odds of all‐cause mortality (OR 5.68; 95% CI 3.98–8.09; I 2 = 30 % ), MACE (OR 4.56; 95% CI 1.97–10.55; I 2 = 47 % ), HF‐related hospitalisation (OR 4.29; 95% CI 2.94–6.26; I 2 = 0 % ) and recurrent MI (OR 1.65; 95% CI 1.15–2.37; I 2 = 0 % ). Pooled estimates were unadjusted; seven studies were synthesised narratively. Conclusion: Elevated H‐FABP is associated with adverse outcomes in ACS, but current evidence does not establish independent prognostic value. Further prospective studies should determine whether H‐FABP adds predictive value beyond established clinical and biochemical risk markers.